title: Sustained leukemia-free state and molecular response to sorafenib in a patient with chronic myelomonocytic leukemia in transformation driven by homozygous FLT3-ITD malignant hematopoiesis.
authors.affiliation: Service d'Hématologie Biologique, Hôpital Cochin, AP-HP, Paris, France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Kosmider
authors.forename: Nicolas
authors.initials: N
authors.lastname: Chapuis
authors.forename: Sophie
authors.initials: S
authors.lastname: Kaltenbach
authors.forename: Romain
authors.initials: R
authors.lastname: Coriat
authors.forename: Pascaline
authors.initials: P
authors.lastname: Boudou Rouquette
authors.forename: Lise
authors.initials: L
authors.lastname: Willems
authors.forename: Virginie
authors.initials: V
authors.lastname: Chesnais
authors.forename: Isabelle
authors.initials: I
authors.lastname: Radford-Weiss
authors.forename: Valerie
authors.initials: V
authors.lastname: Bardet
authors.forename: Patrick
authors.initials: P
authors.lastname: Mayeux
authors.forename: Jerome
authors.initials: J
authors.lastname: Tamburini
authors.forename: Michaela
authors.initials: M
authors.lastname: Fontenay
authors.forename: Didier
authors.initials: D
authors.lastname: Bouscary
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006410:Hematopoiesis; D006801:Humans; D015477:Leukemia, Myelomonocytic, Chronic / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D008875:Middle Aged; D009536:Niacinamide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009693:Nucleic Acid Hybridization; D010671:Phenylurea Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D000077157:Sorafenib; D051941:fms-Like Tyrosine Kinase 3 / Q000276:immunology*
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3